Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results

P. Scilipoti, M. Longoni, M. de Angelis, P. Zaurito, A. Massiet, D. Dutto, F. Soria, M. Álvarez-Maestro, AA. Bazán, B. Pradere, T. Klatte, R. Contieri, R. Hurle, W. Krajewski, JD. Subiela, R. Pichler, A. Szostek, G. Marcq, JLR. Elena, J. Aranda,...

. 2025 ; 135 (6) : 969-976. [pub] 20250111

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015571

OBJECTIVE: To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous Bacillus Calmette-Guérin (BCG) treatment. MATERIALS AND METHODS: Data were retrospectively collected from 95 patients with NMIBC, treated with Gem/Doce at 12 European centres between 2021 and 2024. Patients previously treated with BCG who had completed a full induction course and received at least one follow-up evaluation were included. One-year disease-free survival (DFS), high-grade DFS and progression-free survival (PFS) were estimated using Kaplan-Meier curves. Adverse events (AEs) were recorded through medical interviews. RESULTS: Of 75 patients, 63 (84%) were classified as having high-risk and 12 (16%) as having very-high-risk NMIBC. Over a median (interquartile range) follow-up of 9 (5-14) months, 20 patients (27%) relapsed and five (6.7%) underwent radical cystectomy. The 1-year DFS was 73% (95% confidence interval [CI] 62-86%), 1-year high-grade DFS was 79% (95% CI 68-91%) and 1-year PFS was 95% (95% CI 90-100%). AEs occurred in 34 patients (45%), with six (8.7%) experiencing severe AEs. Limitations of the study include the short follow-up and variability in both treatment dwelling times and dosage across centres. CONCLUSION: The intravesical Gem/Doce regimen demonstrated promising short-term oncological outcomes and was well tolerated in this cohort of patients with high- and very-high-risk NMIBC previously treated with BCG. Prospective studies and randomised trials are awaited to define the ideal candidates for Gem/Doce therapy and to standardise treatment protocols.

Department of Minimally Invasive and Robotic Urology Wrocław Medical University Wrocław Poland

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Bichat Claude Bernard Hospital AP HP Université de Paris Cité Paris France

Department of Urology Claude Huriez Hospital CHU Lille Lille France

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology GRC no 5 Predictive Onco Urology AP HP Hôpital Pitié Salpêtrière Sorbonne Université Paris France

Department of Urology Helios Klinikum Bad Saarow Bad Saarow Germany

Department of Urology Hospital Universitario de Cáceres Cáceres Spain

Department of Urology Hospital Universitario La Paz Madrid Spain

Department of Urology Humanitas Clinical and Research Institute IRCCS Milan Italy

Department of Urology Instituto Ramón y Cajal de Investigación Sanitaria Hospital Universitario Ramón y Cajal Universidad de Alcalá Madrid Spain

Department of Urology Medical University of Innsbruck Innsbruck Austria

Department of Urology University of Texas Southwestern Dallas TX USA

Department of Urology UROSUD La Croix Du Sud Hospital Quint Fonsegrives France

Department of Urology Weill Cornell Medical College New York NY USA

Division of Experimental Oncology Unit of Urology IRCCS Ospedale San Raffaele Milan Italy

Division of Urology Department of Surgical Sciences San Giovanni Battista Hospital University of Studies of Torino Turin Italy

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Vita Salute San Raffaele University Milan Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015571
003      
CZ-PrNML
005      
20250731091102.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.16645 $2 doi
035    __
$a (PubMed)39797535
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Scilipoti, Pietro $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0009000761269889
245    10
$a Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results / $c P. Scilipoti, M. Longoni, M. de Angelis, P. Zaurito, A. Massiet, D. Dutto, F. Soria, M. Álvarez-Maestro, AA. Bazán, B. Pradere, T. Klatte, R. Contieri, R. Hurle, W. Krajewski, JD. Subiela, R. Pichler, A. Szostek, G. Marcq, JLR. Elena, J. Aranda, P. Gontero, M. Rouprêt, SF. Shariat, A. Necchi, F. Montorsi, A. Briganti, E. Xylinas, M. Moschini, EuroGemDoce Study Group Collaborators, European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group
520    9_
$a OBJECTIVE: To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous Bacillus Calmette-Guérin (BCG) treatment. MATERIALS AND METHODS: Data were retrospectively collected from 95 patients with NMIBC, treated with Gem/Doce at 12 European centres between 2021 and 2024. Patients previously treated with BCG who had completed a full induction course and received at least one follow-up evaluation were included. One-year disease-free survival (DFS), high-grade DFS and progression-free survival (PFS) were estimated using Kaplan-Meier curves. Adverse events (AEs) were recorded through medical interviews. RESULTS: Of 75 patients, 63 (84%) were classified as having high-risk and 12 (16%) as having very-high-risk NMIBC. Over a median (interquartile range) follow-up of 9 (5-14) months, 20 patients (27%) relapsed and five (6.7%) underwent radical cystectomy. The 1-year DFS was 73% (95% confidence interval [CI] 62-86%), 1-year high-grade DFS was 79% (95% CI 68-91%) and 1-year PFS was 95% (95% CI 90-100%). AEs occurred in 34 patients (45%), with six (8.7%) experiencing severe AEs. Limitations of the study include the short follow-up and variability in both treatment dwelling times and dosage across centres. CONCLUSION: The intravesical Gem/Doce regimen demonstrated promising short-term oncological outcomes and was well tolerated in this cohort of patients with high- and very-high-risk NMIBC previously treated with BCG. Prospective studies and randomised trials are awaited to define the ideal candidates for Gem/Doce therapy and to standardise treatment protocols.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x farmakoterapie $x patologie $x mortalita $7 D001749
650    _2
$a gemcitabin $7 D000093542
650    12
$a deoxycytidin $x analogy a deriváty $x aplikace a dávkování $x škodlivé účinky $7 D003841
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a docetaxel $x aplikace a dávkování $x škodlivé účinky $7 D000077143
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a lidé středního věku $7 D008875
650    _2
$a aplikace intravezikální $7 D000283
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a BCG vakcína $x terapeutické užití $7 D001500
650    _2
$a nádory močového měchýře neinvadující svalovinu $7 D000093284
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Longoni, Mattia $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a de Angelis, Mario $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0009000804947839
700    1_
$a Zaurito, Paolo $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Massiet, Albane $u Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris Cité, Paris, France
700    1_
$a Dutto, Daniele $u Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy
700    1_
$a Soria, Francesco $u Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy $1 https://orcid.org/0000000184438453
700    1_
$a Álvarez-Maestro, Mario $u Department of Urology, Hospital Universitario La Paz, Madrid, Spain
700    1_
$a Bazán, Alfredo Aguilera $u Department of Urology, Hospital Universitario La Paz, Madrid, Spain
700    1_
$a Pradere, Benjamin $u Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France
700    1_
$a Klatte, Tobias $u Department of Urology, Helios Klinikum Bad Saarow, Bad Saarow, Germany $1 https://orcid.org/0000000243926861
700    1_
$a Contieri, Roberto $u Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy $1 https://orcid.org/0000000170110537
700    1_
$a Hurle, Rodolfo $u Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy
700    1_
$a Krajewski, Wojciech $u Department of Minimally Invasive and Robotic Urology, Wrocław Medical University, Wrocław, Poland
700    1_
$a Subiela, José Daniel $u Department of Urology, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain $1 https://orcid.org/0000000341768174
700    1_
$a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000152869048
700    1_
$a Szostek, Aleksandra $u Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France
700    1_
$a Marcq, Gautier $u Department of Urology, Claude Huriez Hospital, CHU Lille, Lille, France
700    1_
$a Elena, José Luis Rodríguez $u Department of Urology, Hospital Universitario de Cáceres, Cáceres, Spain
700    1_
$a Aranda, Javier $u Department of Urology, Hospital Universitario de Cáceres, Cáceres, Spain
700    1_
$a Gontero, Paolo $u Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy
700    1_
$a Rouprêt, Morgan $u Department of Urology, GRC no 5, Predictive Onco-Urology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Necchi, Andrea $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Montorsi, Francesco $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0000000272674181 $7 xx0084280
700    1_
$a Briganti, Alberto $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Xylinas, Evanguelos $u Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris Cité, Paris, France
700    1_
$a Moschini, Marco $u Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy
710    2_
$a EuroGemDoce Study Group Collaborators
710    2_
$a European Association of Urology ‐ Young Academic Urologists (EAU‐YAU)
710    2_
$a Urothelial Carcinoma Working Group
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 135, č. 6 (2025), s. 969-976
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39797535 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091057 $b ABA008
999    __
$a ok $b bmc $g 2366427 $s 1252696
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 135 $c 6 $d 969-976 $e 20250111 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20250708
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace